These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 32945575

  • 41. Partial external mitral annuloplasty in dogs with myxomatous mitral valve degeneration and congestive heart failure: outcome in 9 cases.
    de Andrade JN, Christopher Orton E, Boon J, Nishimori CT, Olivaes C, Camacho AA.
    J Vet Cardiol; 2011 Sep; 13(3):197-201. PubMed ID: 21824833
    [Abstract] [Full Text] [Related]

  • 42. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE.
    J Vet Intern Med; 2009 Sep; 23(6):1190-6. PubMed ID: 19780931
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Neutrophil-to-lymphocyte ratio is increased in dogs with acute congestive heart failure secondary to myxomatous mitral valve disease compared to both dogs with heart murmurs and healthy controls.
    DeProspero DJ, Hess RS, Silverstein DC.
    J Am Vet Med Assoc; 2023 Nov 01; 261(11):1-8. PubMed ID: 37406992
    [Abstract] [Full Text] [Related]

  • 46. Intravenous administration of allogeneic Wharton jelly-derived mesenchymal stem cells for treatment of dogs with congestive heart failure secondary to myxomatous mitral valve disease.
    Yang VK, Meola DM, Davis A, Barton B, Hoffman AM.
    Am J Vet Res; 2021 Jun 01; 82(6):487-493. PubMed ID: 34032485
    [Abstract] [Full Text] [Related]

  • 47. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
    Klein S, Nolte I, Rumstedt K, Sehn M, Raue JF, Weiner F, Treese JS, Beyerbach M, Bach JP.
    BMC Vet Res; 2021 Sep 25; 17(1):310. PubMed ID: 34563187
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
    Kaplan JL, Visser LC, Gunther-Harrington CT, Ontiveros ES, Wittenburg LA, Palm CA, Stern JA.
    J Vet Intern Med; 2022 Nov 25; 36(6):1892-1899. PubMed ID: 36098206
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease.
    Ward JL, Chou YY, Yuan L, Dorman KS, Mochel JP.
    J Vet Intern Med; 2021 Sep 25; 35(5):2102-2111. PubMed ID: 34387901
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy.
    Borgarelli M, Haggstrom J.
    Vet Clin North Am Small Anim Pract; 2010 Jul 25; 40(4):651-63. PubMed ID: 20610017
    [Abstract] [Full Text] [Related]

  • 55. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K, Kawamoto S, Osuga T, Morita T, Sasaki N, Morishita K, Ohta H, Takiguchi M.
    J Vet Intern Med; 2017 Mar 25; 31(2):316-325. PubMed ID: 28145607
    [Abstract] [Full Text] [Related]

  • 56. Radiographic lung congestion scores in dogs with acute congestive heart failure caused by myxomatous mitral valve disease.
    Koster L, Vogel J, Springer CM, Hecht S.
    J Vet Intern Med; 2023 Mar 25; 37(6):1983-1991. PubMed ID: 37694988
    [Abstract] [Full Text] [Related]

  • 57. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
    Morgan KRS, Monteith G, Raheb S, Colpitts M, Fonfara S.
    Vet J; 2020 Sep 25; 263():105518. PubMed ID: 32928487
    [Abstract] [Full Text] [Related]

  • 58. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency.
    Atkins CE, Keene BW, Brown WA, Coats JR, Crawford MA, DeFrancesco TC, Edwards NJ, Fox PR, Lehmkuhl LB, Luethy MW, Meurs KM, Petrie JP, Pipers FS, Rosenthal SL, Sidley JA, Straus JH.
    J Am Vet Med Assoc; 2007 Oct 01; 231(7):1061-9. PubMed ID: 17916031
    [Abstract] [Full Text] [Related]

  • 59. Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease.
    Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA.
    J Am Heart Assoc; 2021 May 04; 10(9):e018923. PubMed ID: 33890477
    [Abstract] [Full Text] [Related]

  • 60. Tissue Doppler and strain imaging in dogs with myxomatous mitral valve disease in different stages of congestive heart failure.
    Tidholm A, Ljungvall I, Höglund K, Westling AB, Häggström J.
    J Vet Intern Med; 2009 May 04; 23(6):1197-207. PubMed ID: 19909428
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.